Related Experiment Video
Updated: Mar 17, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
[Hypercholesterolemia - Where are we today? Where are we going?]
1Herzzentrum, Medizinische Klinik B, Klinikum Ludwigshafen, Ludwigshafen, Deutschland. gitt@stiftung-ihf.de.
Insights
High LDL cholesterol increases atherosclerosis and cardiovascular risk. Achieving target LDL cholesterol levels, often below 70 mg/dL for high-risk patients, requires more aggressive lipid-lowering therapies like high-dose statins or combination treatments.
Area of Science:
- Cardiology
- Metabolic Disorders
- Pharmacology
Background:
- Hypercholesterolemia is a key modifiable risk factor for atherosclerosis and cardiovascular disease.
- Elevated LDL cholesterol levels significantly increase the risk of cardiovascular ischemic events.
- Current guidelines recommend strict LDL cholesterol goals (<70 mg/dL) for high-risk individuals.
Purpose of the Study:
- To evaluate the effectiveness of current lipid-lowering strategies in achieving guideline-recommended LDL cholesterol goals.
- To identify barriers to goal attainment in high-risk patient populations.
- To discuss potential therapeutic advancements for optimizing LDL cholesterol reduction.
Main Methods:
- Analysis of data from randomized trials and observational studies on lipid-lowering therapies.
- Review of current clinical practice guidelines for hypercholesterolemia management.
- Assessment of treatment patterns and goal achievement rates in high-risk patients.
Main Results:
- Only approximately 20% of treated high-risk patients achieve the recommended LDL cholesterol goal in routine clinical practice.
- Many high-risk patients are undertreated, often receiving low to moderate statin dosages.
- Significant gaps exist between guideline recommendations and real-world LDL cholesterol management.
Conclusions:
- Current therapeutic approaches are insufficient for achieving target LDL cholesterol levels in a majority of high-risk patients.
- Intensified lipid-lowering strategies, including high-dose statins, statin-ezetimibe combination therapy, and novel agents like PCSK9 inhibitors, are necessary.
- Improved adherence to guidelines and enhanced cardiac rehabilitation programs are crucial for reducing cardiovascular risk.
Abstract:
Hypercholesterolemia is one of the major modifiable risk factors for the development of atherosclerosis. Increasing LDL cholesterol is associated with an increased risk of developing cardiovascular diseases as well as cardiovascular ischemic complications. Studies with statins and ultimately with ezetimibe have been able to impressively demonstrate that lowering LDL cholesterol contributes to a significant reduction of cardiovascular ischemic complications.Based on the results of randomized trials for lipid lowering, the practice guidelines developed by the professional societies have defined LDL cholesterol goals. High-risk patients, such as patients with clinically manifest cardiovascular disease, type 2 diabetes, type 1 diabetes with organ damage, moderate or severe chronic kidney disease or a risk of SCORE ≥10 %, should reach LDL cholesterol values <70 mg/dl. Data from observational trials demonstrated that in daily practice only about 20 % of treated high-risk patients reached this recommended LDL cholesterol goal. The therapeutic options are not yet exhausted; patients are treated mainly with low or at most average statin dosages. There should be more potent and high-dose statins used as well as the combination therapy of statin and ezetimibe to achieve the recommended LDL cholesterol goals. Specific cardiac rehabilitation and prevention programs with regular benchmarking could support improved goal-achievement. The new therapeutic option of PCSK9 inhibitors, which significantly and safely lower LDL cholesterol on top of statins and ezetimibe, is currently investigated in large randomized outcome trials.
Related Concept Videos
Cholesterol: Significance and Regulation
Considering cholesterol and...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Pharmacogenomics: Identification of New Drug Targets
Atherosclerosis III: Management
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Lipids: Dietary Sources and Requirements

